Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

Emerging therapeutics for ocular surface disease.

Publication ,  Journal Article
Bielory, BP; Shah, SP; O'Brien, TP; Perez, VL; Bielory, L
Published in: Curr Opin Allergy Clin Immunol
October 2016

PURPOSE OF REVIEW: The present review provides an overview on the potential of different systemic and topical treatments in chronic forms of ocular allergy and dry eye disorder (DED). The impact on anterior surface of ocular inflammatory disorder encompasses an array of conditions, which are frequently underreported. This can contribute to underdiagnoses and ineffective management from healthcare providers such as an allergist and/or ophthalmologist who routinely provide care for these common disorders. Owing to the current limited therapeutic options, healthcare providers are routinely seeking alternative treatments that could facilitate effective management of the conditions. RECENT FINDINGS: Recent advances in immunopathophysiology of ocular surface disorders has provided new potential targets and therapeutic strategies for the treatment of DED and ocular allergy that may include various immunobiological modulators. These modulators have focused on regulating the Th1 and Th2 immune-mediated inflammatory pathways that inhibit various cytokines (e.g. IL-1, IL-4, IL-5, IL-9, IL-13) antibodies (e.g. IgE), and other surface markers of various cell lines (e.g. activated T-lymphocytes, lymphocyte function-associated antigen-1). SUMMARY: Recent findings about the pathophysiology of DED and ocular allergy have led to the greater understanding of the molecular and cellular mechanisms of ocular surface diseases leading to the potential novel targets for immunomodulation of anterior surface ocular disorders. New topical glucocorticoids, leukotriene receptor antagonists, IL-1 antagonists, IL-5, IL-4/IL-13 antagonists, integrin antagonists, and quinolone derivatives appear to be encouraging.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Opin Allergy Clin Immunol

DOI

EISSN

1473-6322

Publication Date

October 2016

Volume

16

Issue

5

Start / End Page

477 / 486

Location

United States

Related Subject Headings

  • Th1-Th2 Balance
  • Quinolones
  • Leukotriene Antagonists
  • Inflammation
  • Immunotherapy
  • Immunoglobulin E
  • Hypersensitivity
  • Humans
  • Glucocorticoids
  • Eye
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bielory, B. P., Shah, S. P., O’Brien, T. P., Perez, V. L., & Bielory, L. (2016). Emerging therapeutics for ocular surface disease. Curr Opin Allergy Clin Immunol, 16(5), 477–486. https://doi.org/10.1097/ACI.0000000000000309
Bielory, Brett P., Steven P. Shah, Terrence P. O’Brien, Victor L. Perez, and Leonard Bielory. “Emerging therapeutics for ocular surface disease.Curr Opin Allergy Clin Immunol 16, no. 5 (October 2016): 477–86. https://doi.org/10.1097/ACI.0000000000000309.
Bielory BP, Shah SP, O’Brien TP, Perez VL, Bielory L. Emerging therapeutics for ocular surface disease. Curr Opin Allergy Clin Immunol. 2016 Oct;16(5):477–86.
Bielory, Brett P., et al. “Emerging therapeutics for ocular surface disease.Curr Opin Allergy Clin Immunol, vol. 16, no. 5, Oct. 2016, pp. 477–86. Pubmed, doi:10.1097/ACI.0000000000000309.
Bielory BP, Shah SP, O’Brien TP, Perez VL, Bielory L. Emerging therapeutics for ocular surface disease. Curr Opin Allergy Clin Immunol. 2016 Oct;16(5):477–486.

Published In

Curr Opin Allergy Clin Immunol

DOI

EISSN

1473-6322

Publication Date

October 2016

Volume

16

Issue

5

Start / End Page

477 / 486

Location

United States

Related Subject Headings

  • Th1-Th2 Balance
  • Quinolones
  • Leukotriene Antagonists
  • Inflammation
  • Immunotherapy
  • Immunoglobulin E
  • Hypersensitivity
  • Humans
  • Glucocorticoids
  • Eye